Resolution of ocular involvement with systemic eculizumab therapy in atypical hemolytic-uremic syndrome

被引：19
|
作者：
David, R. [1 ]
Hochberg-Klein, S. [2 ]
Amer, R. [1 ]
机构：
[1] Hadassah Hebrew Univ Hosp, Dept Ophthalmol, Jerusalem, Israel
[2] Hadassah Hebrew Univ Hosp, Dept Hematol, Jerusalem, Israel
来源：
EYE | 2013年 / 27卷 / 08期
关键词：
D O I：
10.1038/eye.2013.111
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：997 / 998
页数：2
相关论文
共 50 条
  • [1] Resolution of ocular involvement with systemic eculizumab therapy in atypical hemolytic-uremic syndrome
    R David
    S Hochberg-Klein
    R Amer
    [J]. Eye, 2013, 27 : 997 - 998
  • [2] Eculizumab in Atypical Hemolytic-Uremic Syndrome
    Ring, Troels
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1377 - 1378
  • [3] Eculizumab in Atypical Hemolytic-Uremic Syndrome Reply
    Legendre, Christophe M.
    Licht, Christoph
    Loirat, Chantal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1379 - 1380
  • [4] Eculizumab for Atypical Hemolytic-Uremic Syndrome.
    Nuernberger, Jens
    Witzke, Oliver
    Saez, Anabelle Opazo
    Vester, Udo
    Baba, Hideo Andreas
    Kribben, Andreas
    Zimmerhackl, Lothar Bernd
    Janecke, Andreas R.
    Nagel, Mato
    Kirschfink, Michael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05): : 542 - 544
  • [5] OCULAR INVOLVEMENT IN HEMOLYTIC-UREMIC SYNDROME
    SIEGLER, RL
    BREWER, ED
    SWARTZ, M
    [J]. JOURNAL OF PEDIATRICS, 1988, 112 (04): : 594 - 597
  • [6] Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome.
    Gruppo, Ralph A.
    Rother, Russell P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (05): : 544 - 546
  • [7] More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome
    Shin, Jae Il
    Lee, Jae Seung
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20): : 2142 - 2143
  • [8] More on Eculizumab for Congenital Atypical Hemolytic-Uremic Syndrome Reply
    Gruppo, Ralph A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20): : 2143 - 2143
  • [9] Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
    Legendre, C. M.
    Licht, C.
    Muus, P.
    Greenbaum, L. A.
    Babu, S.
    Bedrosian, C.
    Bingham, C.
    Cohen, D. J.
    Delmas, Y.
    Douglas, K.
    Eitner, F.
    Feldkamp, T.
    Fouque, D.
    Furman, R. R.
    Gaber, O.
    Herthelius, M.
    Hourmant, M.
    Karpman, D.
    Lebranchu, Y.
    Mariat, C.
    Menne, J.
    Moulin, B.
    Nuernberger, J.
    Ogawa, M.
    Remuzzi, G.
    Richard, T.
    Sberro-Soussan, R.
    Severino, B.
    Sheerin, N. S.
    Trivelli, A.
    Zimmerhackl, L. B.
    Goodship, T.
    Loirat, C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (23): : 2169 - 2181
  • [10] Gemcitabine-Associated Atypical Hemolytic-Uremic Syndrome Treated with Eculizumab
    Plesa, A.
    Suarez, A.
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2020, 73 (01): : 77 - 78
12345